Merck’s M Ventures supports Nucleai’s spatial AI biomarker technology for clinical trial enrolment

Nucleai  has raised $14 million in funding led by Merck’s M Ventures, with existing investors’ support, bringing total funding to $60 million. This investment enables Nucleai to deploy its AI algorithms for patient enrolment in clinical trials, enhancing personalized medicine. Their AI technology analyzes pathology images to provide insights into cellular interactions, aiding in drug development and personalized treatment. Nucleai’s approach improves clinical trial participant selection, expediting therapy development and offering more effective treatments.

Avi Veidman, CEO and Co-Founder of Nucleai, says,

M Ventures’ investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics. Our vision is that every next-generation therapeutic is accompanied with an AI-enabled companion diagnostic, ensuring that each patient’s treatment pathway is informed and efficacious. This funding positions us to scale spatial AI, not just to intercept but anticipate the complex behavior of diseases.

Access to their full press release here